https://www.thebodypro.com/category/hiv-treatments-in-development/tag/international-aids-conference
HIV Treatments in Development

International AIDS Conference

The Latest

Promo Image

Potent Antiretroviral Effect Seen With the Integrase Inhibitor MK-0518 as Part of Combination ART in Treatment-Naive, HIV-1-Infected Patients

Integrase is an HIV enzyme that allows the HIV virus to insert its genetic material into the DNA of human T cells. HIV integrase inhibition is a new mechanism of viral inhibition that blocks this step in the life cycle of HIV, thus preventing HIV fro...

Promo Image

Aplaviroc's Potency Against HIV Is Linked to Its Slow Dissociation From the CCR5 Receptor

Despite the decision by GlaxoSmithKline (Glaxo) to halt further clinical study of aplaviroc (GSK873140) in treatment-naive patients due to reports of hepatotoxicity in phase 2 trials, research on this and other CCR5 antagonists continues with the hop...

Promo Image

Brecanavir Shows Favorable Pharmacokinetics When Combined With Select PIs in Double-Boosted Regimens

Brecanavir (BCV, GW640385) is a new protease inhibitor (PI) in phase 2b clinical development by GlaxoSmithKline (Glaxo). It has shown powerful antiviral activity against both wild-type and highly drug-resistant HIV. One of its main attributes is that...